You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis

Mäkinen, Petri I.a; Ylä-Herttuala, Seppoa,b,c

Current Opinion in Lipidology:
doi: 10.1097/MOL.0b013e32835da13c
GENETICS AND MOLECULAR BIOLOGY: Edited by Robert Hegele
Abstract

Purpose of review: Despite improved therapies, cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Therefore, new therapeutic approaches are still needed. In the gene therapy field, RNA interference (RNAi) and regulation of microRNAs (miRNAs) have gained a lot of attention in addition to traditional overexpression based strategies. Here, recent findings in therapeutic gene silencing and modulation of small RNA expression related to atherogenesis and dyslipidemia are summarized.

Recent findings: Novel gene therapy approaches for the treatment of hyperlipidemia have been addressed. Antisense oligonucleotide and RNAi-based therapies against apolipoprotein B100 and proprotein convertase subtilisin/kexin type 9 have shown already efficacy in preclinical and clinical trials. In addition, several miRNAs dysregulated in atherosclerotic lesions and regulating cholesterol homeostasis have been found, which may represent novel targets for future therapies.

Summary: New therapies for lowering lipid levels are now being tested in clinical trials, and both antisense oligonucleotide and RNAi-based therapies have shown promising results in lowering cholesterol levels. However, the modulation of inflammatory component in atherosclerosis by gene therapy and targeting of the effects to plaques are still difficult challenges.

Author Information

aDepartment of Biotechnology and Molecular Medicine, A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland

bGene Therapy

cReseach Units, Kuopio University Hospital, Kuopio, Finland

Correspondence to Seppo Ylä-Herttuala, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland. Tel: +358 40 355 2075; e-mail: seppo.ylaherttuala@uef.fi

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins